Related Experiment Video

Updated: Aug 16, 2026

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
07:46

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

Role of aztreonam in lower respiratory tract infections

J L Cook1

  • 1Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado.

Urology
|June 1, 1988
PubMed

Insights

Aztreonam offers a safe and effective alternative to aminoglycosides for treating Gram-negative bacterial pneumonias, especially for vulnerable patients. This monobactam antibiotic provides good drug levels in the lungs with reduced toxicity concerns.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Pulmonology

Background:

  • Gram-negative bacterial pneumonia is a significant cause of illness and death in hospitalized and immunocompromised individuals.
  • Aminoglycoside antibiotics are common treatments but are limited by dose-related kidney and ear toxicity.
  • There is a need for safer, effective alternatives to aminoglycosides for treating these infections.

Purpose of the Study:

  • To evaluate aztreonam as an alternative antibiotic for Gram-negative bacterial pneumonias.
  • To compare the efficacy and safety of aztreonam with aminoglycosides.

Main Methods:

  • Clinical trials were conducted comparing aztreonam and aminoglycoside regimens.
  • Efficacy was assessed based on treatment outcomes for Gram-negative pneumonias.
  • Safety profiles, including nephrotoxicity and ototoxicity, were evaluated.

Main Results:

  • Aztreonam achieves high serum levels and adequate concentrations in bronchial secretions and lung tissue.
  • The monobactam antibiotic demonstrated efficacy against key Gram-negative pathogens.
  • Early clinical trials suggest aztreonam is a viable alternative to aminoglycosides.

Conclusions:

  • Aztreonam is a safe and effective option for treating Gram-negative bacterial pneumonias.
  • This monobactam antibiotic overcomes the toxicity limitations associated with aminoglycosides.
  • Aztreonam represents a valuable therapeutic choice for specific patient populations.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Microbiota of the Respiratory Tract01:29

Microbiota of the Respiratory Tract

The human respiratory tract, comprising the upper and lower segments, serves as a critical interface with the external environment. The upper respiratory tract (URT)—including the nostrils, sinuses, pharynx, and oropharynx—is heavily colonized by microbes, while the lower respiratory tract (LRT), composed of the larynx, trachea, bronchi, and lungs, was long thought to be sterile. However, recent molecular studies have revealed that the lungs are not devoid of microbes but act more like...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...